In this edition, single-fraction SBRT outcomes for central lung tumors, adjuvant durvalumab extends survival in limited-stage small cell lung cancer and more. Read the full coverage here: Single-fraction SBRT confers 'surprisingly excellent' outcomes for central lung tumors Adjuvant durvalumab extends survival in limited-stage small cell lung cancer Depression among people with head and neck cancers likely underreported, undertreated FDA approves tumor treating fields as part of combination therapy for advanced lung cancer First-line maintenance regimen improves OS, PFS in extensive-stage small cell lung cancer References: Cheng Y, et al. Abstract LBA81. Presented at: European Society for Medical Oncology Congress; Sept. 13-17, 2024; Barcelona, Spain. Malik NK, et al. Abstract 285. Presented at: ASTRO Annual Meeting; Sept. 29-Oct. 2, 2024; Washington, D.C. Martinez MC, et al. JAMA Otolaryngol Head Neck Surg. 2024;doi:10.1001/jamaoto.2024.3233. Press Release Press Release

Ver todos los episodios